ArticleChinese journal of integrative medicine2026
Mechanisms of Tianma Gouteng Yin in Treating Hypertension-Associated Vascular Cognitive Impairment: Insights from Experiments, Network Pharmacology, and Molecular Docking.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate active components of Tianma Gouteng Yin (TMGTY) and its mechanisms in treating hypertension-associated vascular cognitive impairment (VCI).
methodsNetwork pharmacology and molecular docking were used to identify major active ingredients and potential targets of TMGTY in treating hypertension-associated VCI. An in vivo model was established using spontaneously hypertensive rats subjected to unilateral common carotid artery occlusion and a high-salt diet. Rats were randomly divided into 7 groups by a simple randomization method: control, model, sham, low-, medium-, and high-dose TMGTY, and nimodipine groups (n=6). After 28 days of oral administration, blood pressure, behavioral studies, pathological staining, and molecular mechanisms were assessed via tail artery blood pressure monitoring, the morris water maze test, HE staining, immunofluorescence staining, ELISA, and Western blotting.
resultsNetwork analysis identified quercetin, kaempferol, beta-sitosterol, and stigmasterol as key ingredients. Pathway enrichment analysis identified the NF-κB signaling pathway as a key pathway through which TMGTY antagonizes the development of hypertension combined with VCI. Core targets included glyceraldehyde-3-phosphate dehydrogenase (GAPDH), interleukin 6 (IL-6), insulin (INS), tumor necrosis factor (TNF), and tumor protein p53 (TP53), and molecular docking confirmed stable binding to TNF and INS. In vivo experiments demonstrated that TMGTY significantly enhanced cognitive performance and reduced blood pressure. Furthermore, it lowered the levels of pro-inflammatory factors (IL-1β, IL-6, TNF-α, Ang-II) and malondialdehyde (MDA), while elevating superoxide dismutase (SOD) expression (P<0.05 or P<0.01). Immunofluorescence staining further revealed that TMGTY treatment reduced the number of Iba1- and CD16-labeled microglia in the hippocampal CA1 region, thereby alleviating neuroinflammation. Additionally, TMGTY inhibited the expression levels of p-NF-κB p65/NF-κB p65 proteins and attenuated neuroinflammation.
conclusionTMGTY exerts multi-component, multi-target effects on hypertension-associated VCI, mitigating neuroinflammation and oxidative stress via modulation of NF-κB signaling pathway.
Indexed as
Identifiers
41963750What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.